Cargando…
Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
PURPOSE OF REVIEW: This paper summarizes early experiences of telemedicine during the COVID-19 pandemic, the patient and physician experience, limitations in accessibility introduced by telemedicine, and the opportunities and anticipated sustained role of telemedicine for cancer care. RECENT FINDING...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547555/ https://www.ncbi.nlm.nih.gov/pubmed/36208400 http://dx.doi.org/10.1007/s11912-022-01332-x |
_version_ | 1784805289063612416 |
---|---|
author | West, Howard (Jack) Barzi, Afsaneh Wong, Debra |
author_facet | West, Howard (Jack) Barzi, Afsaneh Wong, Debra |
author_sort | West, Howard (Jack) |
collection | PubMed |
description | PURPOSE OF REVIEW: This paper summarizes early experiences of telemedicine during the COVID-19 pandemic, the patient and physician experience, limitations in accessibility introduced by telemedicine, and the opportunities and anticipated sustained role of telemedicine for cancer care. RECENT FINDINGS: Research from a wide range of oncology facilities consistently demonstrates the feasibility of delivering telemedicine services over audio (telephone) and/or video platforms. Emerging work highlights that telemedicine is well suited for a subset of patients and clinical settings and that there are methods by which current disparities could potentially be ameliorated. Several current uncertainties limit the broad applicability of telemedicine longitudinally. SUMMARY: Early responses to the pandemic that included rapid introduction of telemedicine demonstrated the feasibility of audio- and video-based platforms that achieved promising utility, while simultaneously demonstrating disparities based on patient characteristics and infrastructural support. Its long-term role will likely depend greatly on reimbursement and regulatory reform. |
format | Online Article Text |
id | pubmed-9547555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95475552022-10-11 Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? West, Howard (Jack) Barzi, Afsaneh Wong, Debra Curr Oncol Rep Lung Cancer (H Borghaei, Section Editor) PURPOSE OF REVIEW: This paper summarizes early experiences of telemedicine during the COVID-19 pandemic, the patient and physician experience, limitations in accessibility introduced by telemedicine, and the opportunities and anticipated sustained role of telemedicine for cancer care. RECENT FINDINGS: Research from a wide range of oncology facilities consistently demonstrates the feasibility of delivering telemedicine services over audio (telephone) and/or video platforms. Emerging work highlights that telemedicine is well suited for a subset of patients and clinical settings and that there are methods by which current disparities could potentially be ameliorated. Several current uncertainties limit the broad applicability of telemedicine longitudinally. SUMMARY: Early responses to the pandemic that included rapid introduction of telemedicine demonstrated the feasibility of audio- and video-based platforms that achieved promising utility, while simultaneously demonstrating disparities based on patient characteristics and infrastructural support. Its long-term role will likely depend greatly on reimbursement and regulatory reform. Springer US 2022-10-08 2022 /pmc/articles/PMC9547555/ /pubmed/36208400 http://dx.doi.org/10.1007/s11912-022-01332-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Lung Cancer (H Borghaei, Section Editor) West, Howard (Jack) Barzi, Afsaneh Wong, Debra Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? |
title | Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? |
title_full | Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? |
title_fullStr | Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? |
title_full_unstemmed | Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? |
title_short | Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? |
title_sort | telemedicine in cancer care beyond the covid-19 pandemic: oncology 2.0? |
topic | Lung Cancer (H Borghaei, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547555/ https://www.ncbi.nlm.nih.gov/pubmed/36208400 http://dx.doi.org/10.1007/s11912-022-01332-x |
work_keys_str_mv | AT westhowardjack telemedicineincancercarebeyondthecovid19pandemiconcology20 AT barziafsaneh telemedicineincancercarebeyondthecovid19pandemiconcology20 AT wongdebra telemedicineincancercarebeyondthecovid19pandemiconcology20 |